Co-diagnostics, inc. appoints dr. mark poritz as new chief scientific officer

Salt lake city , nov. 1, 2022 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) ("co-dx™" or the "company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome mark poritz, phd as the company's new chief scientific officer ("cso"). dr. poritz is a harvard university and uc san francisco educated molecular biologist with more than 30 years of experience in the application of pcr and related methods to gene cloning, drug discovery, infectious disease diagnostics and aptamer selection, who has also served as a reviewer for more than 30 different nih/niaid study sections focusing on infectious disease diagnostics.
CODX Ratings Summary
CODX Quant Ranking